Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease

Chest. 2022 Jun;161(6):1594-1597. doi: 10.1016/j.chest.2021.12.636. Epub 2021 Dec 16.

CARE-PF Investigators:
Veronica Marcoux, Nasrin Khalil, Gerard Cox, Nathan Hambly, Martin Kolb, Charlene Fell, Jolene Fisher, Shane Shapera, Teresa To, Andrea Gershon, Andrew Halayko, Hélène Manganas, Julie Morisset, Deborah Assayag, Mohsen Sadatsafavi, Pearce Wilcox

¹ Department of Medicine, University of Saskatchewan, Saskatoon, Canada.
² Department of Medicine, University of British Columbia, Vancouver, Canada; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada.
³ Department of Respiratory and Sleep Medicine/Institute for Breathing and Sleep, Austin Health, Heidelberg, Australia; Central Clinical School, Monash University, Melbourne, Australia; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
⁴ Departments of Medicine and Community Health Sciences and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada. Electronic address: kerri.johannson@ahs.ca.

No abstract available

Publication types